Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India.
India
decentralization
hepatitis C
primary health care
simplification
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
17
11
2021
received:
07
08
2021
accepted:
21
11
2021
pubmed:
25
11
2021
medline:
4
3
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
India has a significant burden of hepatitis C virus (HCV) infection and has committed to achieving national elimination by 2030. This will require a substantial scale-up in testing and treatment. The "HEAD-Start Project Delhi" aimed to enhance HCV diagnosis and treatment pathways among the general population. A prospective study was conducted at 5 district hospitals (Arm 1: one-stop shop), 15 polyclinics (Arm 2: referral for viral load (VL) testing and treatment) and 62 screening camps (Arm 3: referral for treatment). HCV prevalence, retention in the HCV care cascade, and turn-around time were measured. Between January and September 2019, 37 425 participants were screened for HCV. The median (IQR) age of participants was 35 (26-48) years, with 50.4% male and 49.6% female. A significantly higher proportion of participants in Arm 1 (93.7%) and Arm 3 (90.3%) received a VL test compared with Arm 2 (52.5%, P < .001). Of those confirmed positive, treatment was initiated at significantly higher rates for participants in both Arms 1 (85.6%) and 2 (73.7%) compared to Arm 3 (41.8%, P < .001). Arm 1 was found to be a cost-saving strategy compared to Arm 2, Arm 3, and no action. Delivery of all services at a single site (district hospitals) resulted in a higher yield of HCV seropositive cases and retention compared with sites where participants were referred elsewhere for VL testing and/or treatment. The highest level of retention in the care cascade was also associated with the shortest turn-around times.
Sections du résumé
BACKGROUND AND AIMS
India has a significant burden of hepatitis C virus (HCV) infection and has committed to achieving national elimination by 2030. This will require a substantial scale-up in testing and treatment. The "HEAD-Start Project Delhi" aimed to enhance HCV diagnosis and treatment pathways among the general population.
METHODS
A prospective study was conducted at 5 district hospitals (Arm 1: one-stop shop), 15 polyclinics (Arm 2: referral for viral load (VL) testing and treatment) and 62 screening camps (Arm 3: referral for treatment). HCV prevalence, retention in the HCV care cascade, and turn-around time were measured.
RESULTS
Between January and September 2019, 37 425 participants were screened for HCV. The median (IQR) age of participants was 35 (26-48) years, with 50.4% male and 49.6% female. A significantly higher proportion of participants in Arm 1 (93.7%) and Arm 3 (90.3%) received a VL test compared with Arm 2 (52.5%, P < .001). Of those confirmed positive, treatment was initiated at significantly higher rates for participants in both Arms 1 (85.6%) and 2 (73.7%) compared to Arm 3 (41.8%, P < .001). Arm 1 was found to be a cost-saving strategy compared to Arm 2, Arm 3, and no action.
CONCLUSIONS
Delivery of all services at a single site (district hospitals) resulted in a higher yield of HCV seropositive cases and retention compared with sites where participants were referred elsewhere for VL testing and/or treatment. The highest level of retention in the care cascade was also associated with the shortest turn-around times.
Identifiants
pubmed: 34817928
doi: 10.1111/liv.15112
pmc: PMC9299915
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
532-540Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : AHRQ HHS
ID : T32 HS022241
Pays : United States
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Viral Hepat. 2019 Jan;26(1):38-47
pubmed: 30199587
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329
pubmed: 30176181
Liver Int. 2011 Jul;31 Suppl 2:61-80
pubmed: 21651703
J Clin Exp Hepatol. 2014 Jun;4(2):85-6
pubmed: 25755543
Ann Intern Med. 2015 Mar 17;162(6):397-406
pubmed: 25775312
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):819
pubmed: 30507463
Liver Int. 2022 Mar;42(3):532-540
pubmed: 34817928